Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002720|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : September 20, 2013
RATIONALE: Surgery to remove axillary lymph nodes may be an effective treatment for women with breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of therapy with or without axillary lymph node dissection following quadrantectomy in treating older women with stage I breast cancer that is estrogen receptor positive.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: tamoxifen citrate Procedure: conventional surgery||Phase 3|
- Compare the efficacy of quadrantectomy with or without axillary lymph node dissection, followed by tamoxifen in terms of local and distant relapse rates and overall survival of patients with stage I, invasive breast cancer.
- Determine the relationship between biological variables, such as hormone receptor status, cell proliferation, and DNA ploidy, and the clinical outcome of the disease in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo quadrantectomy with dissection of level I and II axillary lymph nodes.
- Arm II: Patients undergo quadrantectomy without axillary lymph node dissection. Patients on both arms receive tamoxifen daily for 5 years.
Patients are followed every 4 months for 2 years, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 642 patients will be accrued for this study within 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||642 participants|
|Official Title:||QUADRANTECTOMY PLUS AXILLARY DISSECTION VERSUS QUADRANTECTOMY ALONE IN MAMMOGRAPHIC STAGE T1N0 BREAST CANCER PATIENTS AGED OVER 65 YEARS|
|Study Start Date :||December 1995|
|Study Completion Date :||December 2012|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002720
|Istituto Nazionale per lo Studio e la Cura dei Tumori|
|Milano (Milan), Italy, 20133|
|Study Chair:||Gabriele Martelli, MD||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|